Consumer Freedom Protection Act
This article was originally published in The Tan Sheet
Executive Summary
Bill to amend FD&C Act to allow broad range of health claims introduced in House June 8 by Rep. Helen Chenoweth-Hage (R-Idaho). The measure, HR 4604, would eliminate the current "significant scientific agreement" review standard for health claims, substituting a First Amendment standard allowing verbatim and accurately paraphrased quotes of health claims and nutrient content claims published in statements by federal governmental bodies. Under the First Amendment standard, FDA would be prohibited from denying any health or nutrient content claims unless it determines "no scientific evidence supports the claim and that the claim is inherently misleading." An attempt by the Pearson v. Shalala plaintiffs to secure a preliminary injunction against FDA's ban on four proposed health claims was denied May 24 (1"The Tan Sheet" June 5, p. 14)
You may also be interested in...
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.
FDA 100-Day Health Claim Review Provided In House Bill
FDA would be required to authorize general health claims and "claims based on government statements" within 100 days of receipt under the "Consumer Freedom Protection Act." Currently, the agency has 540 days to review a proposed health claim.